Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

PURPOSE: Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. METHODS: We compared the efficacy and safety of evolocumab in hypercholesterolemic patients selected from the phase 2 and 3 tria...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cardiovasc Drugs Ther
Main Authors: Rosenson, Robert S., Jacobson, Terry A., Preiss, David, Djedjos, C. Stephen, Dent, Ricardo, Bridges, Ian, Miller, Michael
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2016
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919379/
https://ncbi.nlm.nih.gov/pubmed/27240673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-016-6666-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker